Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H27FN4O2 |
Molecular Weight | 397.4763 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)CC1=C2N=C(C)C=C(C)N2N=C1C3=CC=C(OCC[18F])C=C3
InChI
InChIKey=FLZZFWBNYJNHMY-VNRZBHCFSA-N
InChI=1S/C22H27FN4O2/c1-5-26(6-2)20(28)14-19-21(17-7-9-18(10-8-17)29-12-11-23)25-27-16(4)13-15(3)24-22(19)27/h7-10,13H,5-6,11-12,14H2,1-4H3/i23-1
BAY85-8102 (widely known as (18)F-DPA-714) is a specific radioligand for the translocator protein (TSPO). TSPO, formerly known as the peripheral benzodiazepine receptor, is dramatically upregulated under pathologic conditions. BAY85-8102 in combination with positron emission tomography imaging participated in phase I clinical trials for investigation of neuroinflammation in Alzheimer's patients. However, this study was terminated early. Clinical pharmacology/efficacy parameters planned in the protocol were not evaluated at the end of the study
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01009359
Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23582365
Created by
admin on Sat Dec 16 10:15:29 GMT 2023 , Edited by admin on Sat Dec 16 10:15:29 GMT 2023
|
PRIMARY | |||
|
0VMV8Z3972
Created by
admin on Sat Dec 16 10:15:29 GMT 2023 , Edited by admin on Sat Dec 16 10:15:29 GMT 2023
|
PRIMARY | |||
|
958233-09-5
Created by
admin on Sat Dec 16 10:15:29 GMT 2023 , Edited by admin on Sat Dec 16 10:15:29 GMT 2023
|
PRIMARY | |||
|
300000042435
Created by
admin on Sat Dec 16 10:15:29 GMT 2023 , Edited by admin on Sat Dec 16 10:15:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY